The SP $value is ok...Some people on this board pretend that the SP should already be at .50$ up to $2.00.
It doesn't make sense..TLT is just a very small company on a small exchange,with no real revenue,no money and no FDA approved treatments, as a results the SP is exactly were it should be.
Once TLT get BTD and a large pharma deal the SP will climb to a better value,not before.
As of now,the FDA asking TLT for data clarifications is perfectly normal and is an integral part of the FDA trial process.
As we speak TLT-Ruvidar CR% is at 40%...
Ruvidar 40%CR is 70% more potent than Adstiladrin(24%CR and BTD-approved by the FDA).
Ruvidar 40%CR is 115% more potent than Keytruda (19%CR and FDA approved).
All the above bode very well for TLT-Ruvidar, since Adstiladrin with just 24%CR and a very big immuno-deficient restriction did get the FDA-BTD approval(TLT-Ruvidar has no restrictions and can treat 100% of patients).
As we speak,for the first time since that story started,with the pre-BTD submission,TLT has a big foot inside the FDA,with a treatment 70% more potent than the best treatment already approved by the FDA(BTD-approved Adstiladrin,24%CR).
The delays are annoying,but the above give me a nice and reassuring feeling about my investment in TLT.
But that is just me.